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Various cytotoxic processes have been obtained in vitro in relation to the immune 
rejection ofsyngeneic tumor cells. Particular attention has been devoted to cytotoxicity 
mediated by T  lymphocytes (1-4), macrophages  (5, 6), and natural killer cells (7-9). 
Nevertheless,  it  has  proved  difficult  to  establish  definitely  to  what  extent  these 
processes contribute  in  vivo  to  the  rejection of the  various  tumors  that  have  been 
analyzed. On this issue, one criterion of relevance lies in the degree of matching of the 
specificity observed in vitro with that observed in vivo. This requires a  comparison of 
the  effects  of cytotoxic  and  rejection  processes  on  a  number  of different  tumors. 
Unfortunately,  this comparison  is often complicated because tumors differ not  only 
for their tumor-associated antigens but  also for many  other cellular properties that 
influence the outcome of the immune processes both in vitro and in vivo. 
We  have  developed  a  system  of tumor  variants  that  appears  to  be  particularly 
suitable for the study of immunological reactions directed against a  variety of surface 
antigens  obtained  on  the  same  background  cell.  We  reported  that,  by  treating  a 
teratocarcinoma and a  Lewis lung carcinoma cell line with a  mutagen,  we obtained 
a number of cell variants that were rejected by syngeneic mice (turn-) 1 (10,  11). Cross- 
immunization experiments performed in vivo indicated the presence of new antigens 
specific for each  of these  variants  (12).  However,  neither with  teratocarcinoma  nor 
with Lewis lung carcinoma were we able to obtain immune cytotoxic spleen cells that 
showed any specificity for the immunizing tum- variants. 
In the search for the effector that causes the rejection of turn- variants, we thought 
that it would be useful to obtain such variants from an ascitic tumor so as to be able 
to collect effector cells in situ.  We show in the accompanying report (13)  that we were 
able to obtain turn- variants by mutagen  treatment of a  malignant cell line isolated 
from the ascitic mastocytoma P815. The cross-immunization pattern observed in vivo 
with  five variants demonstrated  the presence of singular antigens on  three of them 
(Table  I).  We  report  here  the  existence  of  a  syngeneic  T  lymphocyte-mediated 
cytolysis directed against P815 turn- variants and we compare the results obtained in 
vitro to those obtained in vivo. 
* Fonds National de la Recherche Scientifique, Brussels, Belgium. 
1  Abbreviations used in  this paper." FCS,  fetal calf serum;  HAT,  10  -4 M  hypoxanthine,  3.8  ×  10  -7  M 
aminopterin, and 1.6 X 10  -5 M 2-deoxythymidine; tum  +, variant cells that were capable of forming tumors 
in syngeneic mice; tuna-, variant cells that were incapable of forming tumors in syngeneic mice. 
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Materials and Methods 
Cells.  All the P815 cell clones were cultured in Petri dishes  (Falcon 1001; Falcon Labware, 
Div.  of Becton, Dickinson & Co.,  Oxnard, Calif.)  in Dulbecco's modified Eagle's medium 
(Grand Island Biological Co., Grand Island, N.  Y.) supplemented with  10% fetal calf serum 
(FCS).  They  were  incubated at  37°C  in  an  8%  C02  atmosphere.  Ll210  cells  (a  DBA/2 
leukemia) were grown under the same conditions. 
Azaguanine-resistant  Mutants.  Azaguanine-resistant  mutants were selected in limiting-dilution 
conditions in culture medium that contained 10 or 30 #g/ml of azaguanine (ICN Nutritional 
Biochemicals, Cleveland, Ohio). Only those mutants were used that died in a culture medium 
supplemented with  10  -4 M  hypoxanthine (Merck AG, Darmstadt, Federal Republic of Ger- 
many), 3.8  ×  10  -7 M  aminopterin (ICN  Nutritional Biochemicals), and  1.6  ×  l0  -s M  2- 
deoxythymidine (Merck AG) (HAT). 
Spleen  and  Peritoneal  Cells.  Immune spleen cells  were  taken  from  DBA/2  mice  injected 
intraperitoneally 23 wk earlier with living turn- P815 cells in culture medium without FCS. 
Control mice received the same volume of injection medium. The spleen cells were teased in 
Hanks' balanced salts  solution supplemented with  5%  FCS.  Cell suspensions were  filtered 
through a nylon-mesh gauze (80/~m; Nylon Swiss; Staniar, Manchester, England). Peritoneal 
cells were obtained by rinsing the peritoneal cavity with l0 ml of Hanks' balanced salts solution 
that contained 20 U/ml heparin (Roche, Basel, Switzerland). The cells were centrifuged for 10 
min at 200 g and resuspended in RPMI-1640 medium (Grand Island Biological Co.)  supple- 
mented with 10% FCS and 10  -2 M  Hepes (Sigma Chemical Co., St. Louis, Mo.). 
Mixed Lymphocyte-Tumor  Cell Culture 
STIMULATION WITH IRRADIATED  CELLS.  3 ×  107 immune spleen cells were mixed with P815 
cells killed by gamma irradiation (5,000 rad, Cs source).  The cells were incubated in 20 ml of 
RPMI-1640 medium that contained 10% FCS, 10  -2 M Hepes, and 5 X 10  -6 M 2-mercaptoeth- 
anol (Merck AG) in 50-ml Falcon flasks standing upright (Falcon 3013). After 4 d of incubation 
at  37°C  in  an  8%  CO2  atmosphere,  the  stimulated lymphocytes were  washed  in  Hanks' 
balanced salts solution supplemented with 5% FCS and resuspended in RPMI-1640 medium 
that contained 10% FCS and 10  -2 M  Hepes before assay in the SXCr-release test. 
STIMULATION WITH HAT-sENSITIVE  CELLS.  The stimulator cells were HAT-sensitive,  azagua- 
nine-resistant mutants. The stimulation conditions were the same as above, except  that  the 
medium was supplemented with HAT as described above. The stimulator cells were killed in 
<2 d, whereas the survival of the lymphocytes was not affected. 
Cr-retease Assays.  Target cells  grown in vitro were resuspended at  107 cells/ml of Hanks 
balanced salts solution medium supplemented with 5% FCS and incubated at 37°C with  100 
#Ci/ml of Na[SlCr]O~  (Institut des Radiodl~ments, Fleurus, Belgium).  1 h  later, the labeled 
ceils were washed  first  with 50 ml of Hanks' balanced salts solution medium supplemented 
with 5% FCS, then with 50 ml of RPMI-1640 medium that contained 10% FCS and 10  -2 M 
Hepes. They were resuspended in the same medium, and 50-#1 aliquots that contained 104 cells 
were distributed into microplates (96 wells; Linbro Chemical Co., Hamden, Conn.). Stimulated 
lymphocytes were added in 100 #1 of the same medium. Assays were made in triplicate. The 
plates were centrifuged 5 min at  100 g and incubated 4 h at 37°C in an 8% CO2 atmosphere. 
The plates were then centrifuged again and 75-#1 aliquots of supernate were collected and 
counted. The percentage of ~lCr-specific release was calculated as follows: the percent specific 
release =  (ER -  SR) X 100/(MR -  SR); where ER was the observed experimental 51Cr release, 
SR the spontaneous release measured by incubation  of 104 labeled cells in 150 #1 of RPMI-1640 
medium alone, and MR the maximum release  obtained by adding 50 #1 0.3% Triton X-100 
(Sigma) to the target cells. The spontaneous release  was = 10% of the total label incorporated 
into the cells. 
Lytic Units.  1 lytic unit is defined here as the number of spleen or peritoneal cells that lyse 
50% of 104 target cells in 4 h (9). This number was estimated from the specific release obtained 
at  various effector  to  target  ratios  by  means of the  regression  (1  --  e-kx). The  results are 
expressed  in number of lyric units/106 cells. 
Normalized Number of Lytic Units/lO n Cells.  To compare the lytic activities of an effector cell 
on the immunizing  clone (seif-lysis) and on other clones (cross-lysis), we corrected for differences 1186  IMMUNOGENIG VARIANTS OBTAINED BY  MUTAGENESIS OF P815. II. 
in the general sensitivity of the targets. This was done by dividing the number of lytic units 
obtained with a given effector on a given target by the average number of lytic units obtained 
on the same target with all the effectors. This average was calculated after replacement of the 
self-lysis value by the average number of lytic units of the relevant effector  on all the other 
targets. The corrected values were normalized by dividing them by the average of the corrected 
cross-lysis values of the relevant effector. 
Results 
When adult DBA/2 mice were injected intraperitoneally with 2  ×  105 living cells 
of a number of tum- variants, they completely rejected these cells in <20 d  (Table I). 
After that period, these mice showed a significant protection against the immunizing 
variants, against other P815 turn- variants, and against the original P 1 cells that were 
capable  of forming tumors  in  syngeneic mice  (turn  +)  (13).  We  tested  spleen  and 
peritoneal exudate cells of immune animals for their cytolytic activity. 
Cytolytic  TLymphocytes  in the Peritoneal Cavity.  Mice that rejected a first challenge of 
living P815 turn- cells received a  secondary intraperitoneal injection of 2 ×  105 cells 
of the same tum- variant. After 4  d, all the mastocytoma cells had been eliminated 
from the peritoneal cavity as determined by an agar colony test as described in the 
TABLE  I 
Tumorigenicity  and Specificity  of P815 Clones 
No. of mice with Presence of a specific 
tumors/No,  antigen detected in 
mice injected*  vivo¢ 
Control clone:§ 
tum+: P1  15/15 
Mutagenized clones:l] 
tum-: P21  0/20  + 
P32  2/20  - 
P35  0/20  + 
P60  2/20  Not tested 
P76  6/20  Not tested 
P89  1/20  - 
P91  0/20  + 
tum+: P22  6/6 
P26  6/6 
P30  5/6 
P33  3/3 
P38  6/6 
P40  6/6 
P53  6/6 
P58  6/6 
P87  5/6 
P93  6/6 
* DBA/2 mice were injected intraperitoneally with 2 ×  105 living cells. Mice 
without visible tumors 3 mo after injection were considered negative. 
As demonstrated in the accompanying report (13) with immune protection 
experiments performed either directly or by adoptive transfer. 
§ Clone isolated from the initial P815-X2 population, 
II Clones isolated from a P1 population treated with the mutagen N-methyl- 
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accompanying report  (13). At this time, the peritoneal cells were collected and their 
cytolytic activity was  tested  immediately on  a  number of P815  tum-  variants. A 
significant cytolysis was  obtained, as  shown in Table II.  A  fractionation by nylon 
column indicated that the effector cells were T  lymphocytes. 
As seen in Table II, the peritoneal cells immunized against variants P21  and P32 
preferentially lysed the immunizing variant. A  similar specificity was obtained with 
variants P35  and P91.  None was observed with peritoneal cells immunized against 
P89. 
Cytolysis by Immune  Spleen Cells Stimulated In  Vitro.  Spleen cells of animals that had 
been immunized and boosted so as to contain active peritoneal cells had no direct 
cytolytic activity. However, we observed a strong and specific cytolytic response after 
in vitro stimulation of immune spleen cells with the immunizing turn- clone (Table 
III). Similar results were obtained by stimulating either with  turn- cells killed by 
irradiation or with their azaguanine-resistant, HAT-sensitive homologues in medium 
supplemented with HAT. The splenic effector cells were T  lymphocytes, as shown by 
their presence in nylon-filtered population and by their inactivation with anti-Thy- 
1.2 serum (Table III). 
Little or no specific cytolytic activity was obtained after stimulation of spleen cells 
from naive animals (Table III). Spleen cells from animals immunized 5 d earlier with 
living turn- cells already showed a significant specific cytolysis upon restimulation in 
vitro. The capacity of spleen cells to form cytolytic effector cells upon restimulation 
remained high between  10 d  and 6  mo after immunization. A  specific, but weaker, 
cytolysis could  also  be  obtained with  spleen  cells  from  animals immunized with 
irradiated turn- variants (data not shown). 
TABLE  II 




Peritoneal effector cells*  target ra- 
tio 
Percent specific 51Cr release from target cells 
P21  P32  P35  P89  P91  L1210 
Anti-P21  40:1  91  13  14  <1 
20:1  75  5.7  4.7 
10:1  34  2.0 
Anti-P21, T eell~  10:1  50 
5:1  35 
Anti-P32  20:1  6.6  42  12  <1 
10:1  3.0  23  6.7 
Anti-P32, T cells:]:  20:1  13  68  22 
10:l  7.4  53  -- 
5:1  3  34  -- 
Normal  40:1  ~1  <1  <1  <1 
Anti-P35  30:1  0.8  2.9  30  4.8  3.0 
Anti-P89  30:1  1.8  3.5  8.9  8.4  8.6 
Anti-P91  30:1  0.7  4.4  5  5.4  35.4 
* In experiment 1, DBA/2 mice were in~ected  with 6 X 104 living P21 or P32 cells. 20 d later, they received 
an intraperitoneal boost with 2 ×  10  living cells of the same clone. Control animals were injected and 
boosted with medium alone. The peritoneal cells were collected 3 d later and assayed immediately in a 
4-h 51Cr-release test. In experiment 2, the mice were injected with 2 X 105 cells and boosted 60 d later. 
The peritoneal cells were collected 4 d after the boost. 
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TABLE  III 
Cytolysis by Spleen Cells Stimulated In Vitro 
Effector:  Percent specific 51Cr release from tar- 
Experi-  Spleen effec-  Stimulator cells  target  get cells 
ment  tor cells*  ratio 
P1  P21  P32  P91 
1  Anti-P21  P2l irradiated  10:1  53  75  54  48 
3:1  30  61  30  27 
1:1  15  36  14  13 
(13)~  (31)  (13)  (11) 
Anti-P32  P32 irradiated  10:1  54  47  86  64 
3:1  33  22  68  36 
1:1  18  8  48  18 
(14)  (10)  (68)  (18) 
Anti-P91  P91 irradiated  10: l  29  14  29  76 
3: l  9.2  3.8  11  70 
I:I  3.1  0.3  2.4  43 
(3.9)  (1.7)  (3.0)  (67) 
Normal  P21 irradiated  20:1  17  I1  22 
10:1  8.6  5.9  13 
(1.1)  0,8)  (1.6) 
Normal  P32 irradiated  20:1  29  19  40 
10:1  15  9.4  24 
(2.5)  (1.4)  (3.3) 






P21 azaguanine resistant  10:1  28  78  27 
5:1  16  64  15 
2.5:1  10  53  9.3 
(4.8)  (29)  (3.9) 
P21 azaguanine resistant  10:1  26  76  26 
5:1  14  59  12 
2.5:1  9  47  8.3 
(4.3)  (28)  (4.3) 
P21 azaguanine resistant  20:1  <  1  <  I  2.5 
(<0.07)  (<0.07)  (0.18) 
* DBA/2 mice were immunized with 2 ×  105 living P21, P32, or P91 cells. In experiment 1, the spleen cells 
were collected after 47 d. 3 ×  107 spleen cells were incubated for 4 d with 6 ×  105 irradiated stimulator 
cells. In experiment 2, 3 ×  107 spleen cells collected after 26 d were incubated for 5 d with 2 ×  105 living 
P21 azaguanine-resistant cells in HAT medium. 
Lyric units/106  cells are shown in parentheses. 
§ Filtered once on nylon wool (14). 
]1 Depleted from T lymphocytes by treatment with anti-Thy-l.2 (AKR anti-C3H) serum and complement. 
To  examine  the  possibility  that  the  lytic  response  was  directed  against  FCS 
components bound  on  P815  cells, we immunized  mice with turn-  variants grown in 
mouse serum for >7 d. The results were the same as those obtained after immunization 
with cells grown in FCS  (data not shown). 
Analysis of the turn-  Antigenic  Specificities.  To  examine the pattern  of singular and 
common  antigens found on turn- variants, seven independently isolated clones were 
used to immunize mice and stimulate their spleen cells in vitro. The cytolytic activities 
were  tested  against  these seven  turn-  variants  and  the  turn ÷  clone  P1  (Table  IV). 
Spleen  cells  immunized  and  stimulated  with  P2t,  P32,  P35,  and  P91  showed  a 
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TABLZ IV 
Specificities Defined by Immune Spleen Cell Cytolysis 
1189 
Spleen cffcc-  I,ysis of target ceils 
tor cells*  P  1  P21  P32  P35  P60  P76  P89  P91 
lyric units/ lO 6 cells 
Anti-P2I  3.9  ~  3.4  5.3  4.0  4.1  3.0 
(0.81)§  ](6.44)]  (0.97)  (1.20)  (0.95)  (1.17)  (0.90) 
Anti-P32  27  6.8  ~  22  15  16  16 
(1.20)  (0,88)  1(4.55)]  (1.07)  (0.76)  (0.96)  (1.04) 
Anti-P35  21,7  5.0  l I  ~  16  11  16 
(t 2'0)  (0,81)  (0.86)  1(5.57]  (1.05)  (0,{t5)  (I.32) 
Anti-P60  5,6  2.7  5.2  5  ~  4.9  3,8 
(0.85)  (IA9)  0.07)  (0,82)  ~  (t.00)  (0.83) 
Anti-P76  6.32  2.0  5,1  6.7  8.3  ~  2.5 
(0,9 ]  )  (0,84)  ( 1,01 )  ( 1.05)  (1,39)  I  (2,18) ]  (0,52) 
Anti-P89  15,B  6.0  16  18  18  I 1  1 I 
(0,~)  (0,97)  0.22)  (].~0)  (H6)  (o,ss)  (0.86) 
Anti-Pgl  3.26  1. t  2.7  3.5  3.4  3,7  2.8 













* DBA/2 mice were immunized with 2 ×  10  ~ living turn- variants. 21 d  later, these spleen cells were rt~timulated  in vitro with the irradiated 
immunizing  variant and amayed in a 4-h 6tCr.relell~ t~t on various turn- variants. 
:~ Boxed values were significantly  different  from the mean of the other croa~-lysis  values at a  P -  0.02 level  (Student's t test). 
§ Normalized lytic index  (corrects the differences in general sensitivity  of the various targels)  is shown  in parent hcses, 
a  singular antigenic specificity on each of these variants. No singular specificity  was 
observed on P89.  Variants  P60  and P76  displayed  a  weak, but  significant,  singular 
specificity which was confirmed in a  duplicate experiment. The effectors immunized 
against every tum- variant cross-reacted with all the variants and with the tum  + cells. 
Not  unexpectedly,  we  found  that  lymphocytes  immunized  in  vivo  with  irradiated 
turn  +  ceils  had  a  uniform  cytolytic  activity  against  the  turn-  variants  (data  not 
shown). 
To estimate more precisely the degree of cross-reaction between the different target 
cells,  we normalized  the lysis  values,  taking into  account  the general  sensitivity  of 
each  target  (Materials  and  Methods).  With  this  normalized  lytic  index,  shown  in 
Table  IV,  values  significantly  >1  indicate  that  the  relevant  target  cell  and  the 
immunizing  variant  share  an  antigenic  specificity  that  is  not  found  on  the  other 
targets.  This procedure confirmed that six out of the seven turn- variants carried a 
singular antigenic specificity.  Furthermore, it indicated  that  these six antigens were 
all different, and that at least those strong singular antigens carried by P21, P32, P35, 
and P91  were completely unrelated:  no significant  cross-reaction above that caused 
by the common antigen found on the turn  + cell was observed with any pair of tum- 
variants. 
This analysis has been extended to other tum- variants. From a total of 21 variants 
analyzed so far, we detected no individual antigen on 6, weak individual antigens on 
4,  and  strong individual  antigens  (normalized lytic  index  >2)  on  1 I.  These  turn- 
antigens appeared to be completely unrelated to each other. 
The  number of stimulator cells  added  to the  responder spleen  cells  affected  not 
only the intensity  of the cytolytic  response,  but  also  its  specificity  (Table  V).  The 
highest  and  most  specific  cytolytic  activities  were  observed  with  doses  of  10s-106 
stimulator cells. We checked that our failure to observe a specific antigen on P89 was 
not  a  result  of the  use  of an  improper  dose  of stimulator cells:  no  specificity  was 1190  IMMUNOGENIC VARIANTS OBTAINED BY  MUTAGENESIS OF  P815. II. 
TABLE  V 
Effect of the Number of Stimulator Cells on the Specificity of the Lysis by 
Spleen Cells 
Number of P21 stim- 
ulator cells* 
Lysis of target cells 
PI  P21  P32 
lytic units/lO  8 cells 
6 X  10  s  0.1  0.1  0.1 
2 X l0  s  7.6  14.5  7.5 
6 X 105  10.4  53  17 
2 X l0  b  5.4  44  9.3 
* 3 ×  107 spleen cells from mice immunized 120 d earlier with 2 ×  105 living 
P21 cells were incubated for 4 d with the number of irradiated P21 indicated. 
TABLE  VI 
Absence of Spedfic Antigens on Mutagenixed Cells That Have Retained Their 
Effector cells* 
Tumorigenicity 
Lysis of target ce[ls 
self:~  P 1  P35  P91 
lytic units/ lO  s cells 
Anti-P1  (control)  3.2  4.2  4.6 
Anti-P22  6.9  5.0  4.1  5.3 
Anti-P26  1.4  1.5  1.8  1.2 
Anti-P30  9.4  11.6  8.9  9.5 
Anti-P33  1.3  1.6  1.7  1.3 
Anti-P38  1.9  1.6  2.6  2.2 
Anti-P40  3.4  2.1  3.1  3. l 
Anti-P53  10.6  6.4  8.4  11.5 
Anti-P58  2.2  1.6  2.8  3.3 
Anti-P87  1.8  1.4  2.3  1.3 
Anti-P93  1.2  1.1  2. !  1.1 
* Spleen cells from DBA/2 mice immunized with 6 ×  10  e irradiated cells 50 d 
earlier, stimulated with irradiated cells of the same variant for 4 d. 
:~ Target cells were the immunizing variant. 
observed  after  stimulation  at  doses  ranging  from  3  ×  10  a  to  107  P89  cells/3  X  107 
spleen cells (data not shown). 
Absence  of New  Antigens  on  Mutagenized  Cells  That  Have  Remained  Tumorigenic.  We 
selected  10 P815 clones whose ability to form tumors was unaffected by the mutagenic 
treatment  (Table I). These tum+ clones were isolated from  the mutagenized  popula- 
tion that contained turn- clones P21, P32, P35, and P91. DBA/2  mice were immunized 
with irradiated cells and their spleen cells were restimulated  in vitro. No evidence for 
a  singular antigen was obtained with any of these clones (Table VI). 
turn- and the turn + Antigens Are Recognized by Distinct Populations  of Lymphocytes.  Spleen 
cells recovered  from  mice  immunized  with  P32,  were  stimulated  in  vitro  with  the 
same  variant  and  assayed  for  their  cytolytic  activity  against  different  51Cr-labeled 
P815 targets in the presence of various cold competitor cells (Fig.  1). When  the target 
cell was the immunizing  variant  P32, we found that  this variant was a  more effective 
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FIo.  1.  Spleen cells from DBA/2 mice immunized with 2 x  105 living P32 cells were stimulated in 
vitro with P32 and tested against 51Cr-labeled P32 targets (2.5: l effector:target ratio) or P21 targets 
(20:1 effeetor:target ratio). Cold competitor ceils were added: P1 (O), P21  (A), and P32 (O). 
did not observe this preferential competition by P32. If there was only one population 
of lymphocytes with higher affinity for P32, this variant would compete better than 
the others  against  any P815  target.  Therefore,  immunization  of DBA/2  mice with 
P32 generated two distinct populations of immune lymphocytes: one directed against 
the  individual  specificity of P32  and  another  that  recognized  a  common  antigen 
present on all the turn- variants and on the turn ÷ cells. Similar results were obtained 
with lymphocytes immunized against P21. 
Discussion 
We  have examined  the  cytolytic  reaction  of immune  syngeneic  T  lymphocytes 
against a number of independently isolated P815 turn- variants. From the 21 variants 
analyzed  so far,  15  were  found  to carry new  antigens  that  are not  present  on  the 
original tum÷ cells. The presence of a strong new antigenic specificity detected by T 
lymphocyte-mediated cytolysis appears to be diagnostic for the turn- character: none 
was found on  10 clones that had remained turn + after the mutagenesis. The converse 
is  clearly  not  true:  some  tum-  variants  like  P89  fail  to  show  any  new  antigen 
detectable by T  cell cytolysis. The cause of the rejection of this class of turn- variants 
remains  to be determined.  An  obvious possibility  is  an  increased  expression  of an 
antigen that is already present on the P815 turn ÷ cell. 
The  lymphocytes  immunized  against  each  tum-  variant  exerted  a  significant 
cytolysis against  the.other  variants and  against  the original  turn + clone,  indicating 
the persistence on the tum- variants of an antigen present on the tum÷ cell. This is 
consistent with previous reports which demonstrate that P815 is capable of inducing 
a  syngeneic  cytolysis  (15,  16).  Moreover,  we  found  no  instance  of cross-reaction 
between any pair of tum- clones that could  not  be accounted  for by this common 
turn +  antigen.  The  lfi  turn-  variants  that  carry  new  antigens  all  carry  different 
specificities.  Therefore,  it  is  probable that  the  number of completely independent 
turn- antigens that can be obtained on P815  is >30. This diversity makes it unlikely 
that the tum- antigens appear as a consequence of the induction of viral components 
by the mutagen. 
For five P81fi turn-  variants, it was possible to compare the pattern of specificity 1192  IMMUNOGENIC VARIANTS OBTAINED BY MUTAGENESIS OF  P815. II. 
observed in vitro to that obtained in immune protection experiments described in the 
accompanying report. For variants P21, P35, and P91, specific antigens were detected 
both in vivo and in T  cell-mediated lysis. For variant  P89,  no specific antigen was 
found either in vivo or in vitro. However, variant P32 showed no specificity in vivo, 
whereas it  showed a  definite specificity in T  cell cytolysis. Thus  the pattern  of the 
specificity obtained in T  cell cytolysis matches that observed in vivo very significantly, 
but not completely. Although this correlation favors a  major role of T  cytolytic cells 
in  the  rejection  of  most  P815  tum-  variants,  it  does  not  exclude  other  effector 
mechanisms. In this respect, it should be mentioned that even though teratocarcinoma 
and Lewis lung carcinoma tum- variants generate a very specific immune protection 
in vivo, we have consistently failed to obtain specific cytolytic spleen cells in mice that 
were immunized with these variants.  (11,  12;  and T. Boon, O. Kellermann, A. Van 
Pel, J.  C.  Leclerc, and J.  Van  Snick.  Unpublished  observations.).  It  has also been 
reported that, for the male-specific antigen of the mouse, the rejection of male grafts 
does not correlate well with the presence of cytolytic T  cells (17). 
The  results  described  here suggest  that  the  turn-  variants obtained  in  the  P815 
mastocytoma system may serve as a convenient system for the study ofT lymphocyte- 
mediated cytolysis directed against a variety of antigens on a uniform background. It 
will  he  of interest  to  examine  the  relation  of the  various  turn-  antigens  with  the 
products of the major histocompatibility locus. 
Summary 
Tumor cell  variants that  were rejected by syngeneic mice  (turn-)  were obtained 
from mastocytoma P815  by mutagenesis  (as described  in  the accompanying report 
(13).  A  considerable T  lymphocyte-mediated lysis was observed upon incubation of 
these  turn-  variants  with  peritoneal  exudate  cells  collected  a  few  days  after  an 
intraperitoneal  challenge of immune animals.  Spleen cells from these animals were 
cytolytic after stimulation in vitro with the immunizing variant. 
New antigens, absent from the original P815 turn ÷ cells, were detected on 15 of the 
21  turn-  variants that  were tested.  All  these antigens  appeared to be different.  No 
new antigen was detected on any of 10 mutagenized  P815  clones that  had retained 
their ability to form tumors. 
We compared the evidence obtained in vivo and in vitro for the presence of specific 
antigens on five turn- variants. Three variants were shown both in vivo and in vitro 
to carry an individual  antigen.  One showed no specificity either in vivo or in vitro. 
However, for one variant, no specificity was observed in vivo, although cytolysis tests 
demonstrated the existence of a singular antigenic specificity. 
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